The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference

被引:35
作者
Marquez, Paul
Baliram, Ramkumarie
Kieffer, Brigitte L.
Lutfy, Kabirullah
机构
[1] Western Univ Hlth Sci, Dept Pharmaceut Sci, Coll Pharm, Pomona, CA 91766 USA
[2] ULP, INSERM, CNRS, UMR 7104,U596,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France
关键词
buprenorphine; mu opioid receptor (MOP); knockout mouse; locomotor sensitization; conditioned place preference (CPP); amphetamine;
D O I
10.1016/j.neuropharm.2007.01.005
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The analgesic effect of buprenorphine is mediated via the mu opioid receptor (MOP). In the present study, using mice lacking the MOP and their wild-type littermates, we determined the role of the MOP in buprenorphine-induced locomotor stimulation and conditioned place preference (CPP). Buprenorphine (3 mg/kg) increased motor activity in wild-type but not in MOP knockout mice, showing the motor stimulatory action of buprenorphine is mediated via the MOP. When the mice were given the same treatment once daily for 5 consecutive days and challenged with buprenorphine on day 11, the motor stimulatory action of buprenorphine was enhanced in wild-type but not in MOP knockout mice, showing sensitization developed to the motor stimulatory action of buprenorphine and this phenomenon was mediated via the MOP. Likewise, buprenorphine induced CPP in wild-type mice after four alternate-day saline/buprenorphine (3 mg/kg) injections paired with olfactory and visual cues. However, buprenorphine failed to induce CPP in MOP knockout mice. In contrast, amphetamine (1 mg/kg) induced a comparable CPP in wild-type and MOP knockout mice. Together, the present results suggest that the ability of buprenorphine to increase motor activity and induce locomotor sensitization and CPP is mediated via the MOP. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1336 / 1341
页数:6
相关论文
共 43 条
[1]   Conditioned place preference: what does it add to our preclinical understanding of drug reward? [J].
Bardo, MT ;
Bevins, RA .
PSYCHOPHARMACOLOGY, 2000, 153 (01) :31-43
[2]   Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor [J].
Bloms-Funke, P ;
Gillen, C ;
Schuettler, AJ ;
Wnendt, S .
PEPTIDES, 2000, 21 (07) :1141-1146
[3]   Effect of nociceptin/orphanin FQ on the rewarding properties of morphine [J].
Ciccocioppo, R ;
Angeletti, S ;
Sanna, PP ;
Weiss, F ;
Massi, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) :153-159
[4]   ANIMAL PHARMACOLOGY OF BUPRENORPHINE, AN ORIPAVINE ANALGESIC AGENT [J].
COWAN, A ;
DOXEY, JC ;
HARRY, EJR .
BRITISH JOURNAL OF PHARMACOLOGY, 1977, 60 (04) :547-554
[5]   AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT [J].
COWAN, A ;
LEWIS, JW ;
MACFARLANE, IR .
BRITISH JOURNAL OF PHARMACOLOGY, 1977, 60 (04) :537-545
[6]  
Cowan A, 2003, INT J CLIN PRACT, P3
[7]   Dopamine and drug addiction: the nucleus accumbens shell connection [J].
Di Chiara, G ;
Bassareo, V ;
Fenu, S ;
De Luca, MA ;
Spina, L ;
Cadoni, C ;
Acquas, E ;
Carboni, E ;
Valentini, V ;
Lecca, D .
NEUROPHARMACOLOGY, 2004, 47 :227-241
[8]  
DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
[9]  
DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067
[10]   Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors [J].
Hawkinson, JE ;
Acosta-Burruel, M ;
Espitia, SA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 389 (2-3) :107-114